• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补骨脂素衍生物作为蛋白酶体抑制剂。

Psoralen Derivatives as Inhibitors of Proteasome.

机构信息

University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, SI-1000 Ljubljana, Slovenia.

Department of Medicinal Chemistry, University of Minnesota, 308 Harvard Street Southeast, Minneapolis, MN 55455, USA.

出版信息

Molecules. 2020 Mar 12;25(6):1305. doi: 10.3390/molecules25061305.

DOI:10.3390/molecules25061305
PMID:32178473
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7144120/
Abstract

Protein degradation is a fundamental process in all living organisms. An important part of this system is a multisubunit, barrel-shaped protease complex called the proteasome. This enzyme is directly responsible for the proteolysis of ubiquitin- or pup-tagged proteins to smaller peptides. In this study, we present a series of 92 psoralen derivatives, of which 15 displayed inhibitory potency against the proteasome in low micromolar concentrations. The best inhibitors, i.e., , , and , exhibited a mixed type of inhibition and overall good inhibitory potency in biochemical assays. -(cyanomethyl)acetamide ( = 5.6 µM) and carboxaldehyde-based derivative ( = 14.9 µM) were shown to be reversible inhibitors of the enzyme. On the other hand, pyrrolidine-2,5-dione esters and irreversibly inhibited the enzyme with values of 4.2 µM and 1.1 µM, respectively. In addition, we showed that an established immunoproteasome inhibitor, , is a noncompetitive irreversible inhibitor of the mycobacterial proteasome ( = 5.2 ± 1.9 µM, / = 96 ± 41 M·s). These compounds represent interesting hit compounds for further optimization in the development of new drugs for the treatment of tuberculosis.

摘要

蛋白质降解是所有生物体的基本过程。该系统的一个重要部分是多亚基、桶形蛋白酶复合物,称为蛋白酶体。这种酶直接负责将泛素或 pup 标记的蛋白质降解为较小的肽。在这项研究中,我们提供了一系列 92 种补骨脂素衍生物,其中 15 种在低微摩尔浓度下显示出对蛋白酶体的抑制活性。最好的抑制剂,即 、 、 和 ,在生化测定中表现出混合抑制类型和整体良好的抑制活性。-(氰甲基)乙酰胺( = 5.6 µM)和基于醛的衍生物 ( = 14.9 µM)被证明是酶的可逆抑制剂。另一方面,吡咯烷-2,5-二酮酯 和 分别以 4.2 µM 和 1.1 µM 的 值不可逆地抑制了酶。此外,我们表明,一种已建立的免疫蛋白酶体抑制剂 ,是非竞争性不可逆抑制剂( = 5.2 ± 1.9 µM,/ = 96 ± 41 M·s)。这些化合物代表了有趣的命中化合物,可进一步优化开发用于治疗结核病的新药。

相似文献

1
Psoralen Derivatives as Inhibitors of Proteasome.补骨脂素衍生物作为蛋白酶体抑制剂。
Molecules. 2020 Mar 12;25(6):1305. doi: 10.3390/molecules25061305.
2
Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.靶向对人蛋白酶体活性降低的选择性分枝杆菌ClpP1P2抑制剂
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02307-16. Print 2017 May.
3
Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.基于半胱氨酸和苏氨酸的片段大小和双齿(免疫)蛋白酶体抑制剂靶向弹头。
Cells. 2021 Dec 6;10(12):3431. doi: 10.3390/cells10123431.
4
The Pup-Proteasome System of Mycobacteria.分枝杆菌的 Pup-蛋白酶体系统。
Microbiol Spectr. 2014 Oct;2(5). doi: 10.1128/microbiolspec.MGM2-0008-2013.
5
Macrocyclic Peptides that Selectively Inhibit the Proteasome.大环肽选择性抑制蛋白酶体。
J Med Chem. 2021 May 13;64(9):6262-6272. doi: 10.1021/acs.jmedchem.1c00296. Epub 2021 May 5.
6
Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome.鉴定植物源天然产物作为潜在的结核分枝杆菌蛋白酶体抑制剂。
BMC Complement Altern Med. 2014 Oct 15;14:400. doi: 10.1186/1472-6882-14-400.
7
Development of Tyrphostin Analogues to Study Inhibition of the Mycobacterium tuberculosis Pup Proteasome System*.研究结核分枝杆菌 Pup 蛋白酶体系统抑制作用的 Tyrphostin 类似物的开发*。
Chembiochem. 2021 Nov 3;22(21):3082-3089. doi: 10.1002/cbic.202100333. Epub 2021 Sep 12.
8
Identification of New Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach.基于知识的计算筛选方法鉴定新型蛋白酶体抑制剂。
Molecules. 2021 Apr 16;26(8):2326. doi: 10.3390/molecules26082326.
9
Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors.弹头修饰的补骨脂素的合成与生化评价作为(免疫)蛋白酶体抑制剂。
Molecules. 2021 Jan 12;26(2):356. doi: 10.3390/molecules26020356.
10
Discovery of new proteasome inhibitors using a knowledge-based computational screening approach.使用基于知识的计算筛选方法发现新型蛋白酶体抑制剂。
Mol Divers. 2015 Nov;19(4):1003-19. doi: 10.1007/s11030-015-9624-0. Epub 2015 Aug 1.

引用本文的文献

1
Structural Insights into Bortezomib-Induced Activation of the Caseinolytic Chaperone-Protease System in Mycobacterium tuberculosis.硼替佐米诱导结核分枝杆菌中酪蛋白溶解伴侣-蛋白酶系统激活的结构见解
Nat Commun. 2025 Apr 11;16(1):3466. doi: 10.1038/s41467-025-58410-4.
2
Pharmaceutical Design and Structure-activity Relationships of Psoralen and Derivatives.补骨脂素及其衍生物的药物设计与构效关系
Curr Pharm Des. 2025;31(30):2438-2463. doi: 10.2174/0113816128365838250128060007.
3
Primed for Interactions: Investigating the Primed Substrate Channel of the Proteasome for Improved Molecular Engagement.

本文引用的文献

1
A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors.基于补骨脂素的免疫蛋白酶体抑制剂的聚焦构效关系研究。
Medchemcomm. 2019 Sep 13;10(11):1958-1965. doi: 10.1039/c9md00365g. eCollection 2019 Nov 1.
2
Selective Phenylimidazole-Based Inhibitors of the Proteasome.基于苯并咪唑的蛋白酶体选择性抑制剂。
J Med Chem. 2019 Oct 24;62(20):9246-9253. doi: 10.1021/acs.jmedchem.9b01187. Epub 2019 Oct 15.
3
A Practical Review of Proteasome Pharmacology.蛋白酶体药理学实用综述。
做好相互作用的准备:研究蛋白酶体的预激活底物通道以改善分子结合。
Molecules. 2024 Jul 17;29(14):3356. doi: 10.3390/molecules29143356.
4
Polypharmacology-Driven Discovery and Design of Highly Selective, Dual and Multitargeting Inhibitors of - A Review.多药理学驱动的 - 高选择性、双重和多靶点抑制剂的发现和设计:综述。
Curr Drug Targets. 2024;25(9):620-634. doi: 10.2174/0113894501306302240526160804.
5
pH-Dependent Photoinduced Interconversion of Furocoumaric and Furocoumarinic Acids.呋喃香豆酸和呋喃香豆素酸的pH依赖性光诱导相互转化
Molecules. 2021 May 10;26(9):2800. doi: 10.3390/molecules26092800.
6
Identification of New Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach.基于知识的计算筛选方法鉴定新型蛋白酶体抑制剂。
Molecules. 2021 Apr 16;26(8):2326. doi: 10.3390/molecules26082326.
Pharmacol Rev. 2019 Apr;71(2):170-197. doi: 10.1124/pr.117.015370.
4
Local and global influences on protein turnover in neurons and glia.神经元和神经胶质细胞中蛋白质周转的局部和全局影响。
Elife. 2018 Jun 19;7:e34202. doi: 10.7554/eLife.34202.
5
A patent review of immunoproteasome inhibitors.免疫蛋白酶体抑制剂的专利审查。
Expert Opin Ther Pat. 2018 Jul;28(7):517-540. doi: 10.1080/13543776.2018.1484904. Epub 2018 Jun 14.
6
Targeting the Proteostasis Network for Mycobacterial Drug Discovery.针对蛋白质稳态网络进行分枝杆菌药物研发。
ACS Infect Dis. 2018 Apr 13;4(4):478-498. doi: 10.1021/acsinfecdis.7b00231. Epub 2018 Mar 2.
7
Proteasome substrate capture and gate opening by the accessory factor PafE from .辅助因子 PafE 对. 的蛋白酶体底物捕获和门控打开作用
J Biol Chem. 2018 Mar 30;293(13):4713-4723. doi: 10.1074/jbc.RA117.001471. Epub 2018 Feb 5.
8
Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome.荜茇明碱及其一些类似物对组成型蛋白酶体而言,能选择性地抑制人免疫蛋白酶体。
Biochem Biophys Res Commun. 2018 Feb 12;496(3):961-966. doi: 10.1016/j.bbrc.2018.01.100. Epub 2018 Feb 2.
9
Structure-based design of human immuno- and constitutive proteasomes inhibitors.基于结构的人免疫和组成型蛋白酶体抑制剂的设计。
Eur J Med Chem. 2018 Feb 10;145:570-587. doi: 10.1016/j.ejmech.2018.01.013. Epub 2018 Jan 8.
10
An Overview of Bortezomib-Induced Neurotoxicity.硼替佐米诱导的神经毒性概述。
Toxics. 2015 Jul 27;3(3):294-303. doi: 10.3390/toxics3030294.